P009 - Cardiovascular Disease Burden Before Hereditary Transthyretin Amyloidosis Diagnosis

Description

BACKGROUND/INTRODUCTION • Hereditary transthyretin amyloidosis (hATTR or ATTRv [variant]) is a progressive and fatal disease often associated with infiltrative cardiac involvement • Cardiac involvement in ATTRv is associated with poor survival • Patients often have long-standing cardiac symptoms prior to their amyloidosis diagnosis, and it has been shown that diagnostic delay can result in increased disease burden and progressive myocardial injury and failure • Real-world evidence focusing on cardiac manifestations throughout the ATTRv patient journey is limited • Nurses who work closely with patients with heart failure are positioned to recognize the symptoms and early signs that should raise clinical suspicion and uncover an underlying diagnosis of ATTRv OBJECTIVE • To determine whether patients with ATTRv demonstrate significant cardiovascular symptom manifestations and health care utilization before diagnosis

Speaker(s):

• Montserrat Vera Llonch, Senior Director, HEOR & New Product Strategy, Ionis Pharmaceuticals, Inc.